Display Settings:

Format

Send to:

Choose Destination
Anticancer Drugs. 2011 Apr;22(4):317-23. doi: 10.1097/CAD.0b013e328343e076.

Oxaliplatin as a radiosensitizing agent in rectal cancer.

Author information

  • 1University of Texas Southwestern Medical Center, Dallas, Texas 75216, USA. Sergio.huerta@utsouthwestern.edu

Abstract

The efficacy of oxaliplatin monotherapy against several solid tumors and its relative lack of nephrotoxicity and myelosupression, coupled with results of the Multicenter International Study of Oxaliplatin/5-Fluorouracil/Leucovorin in the Adjuvant Treatment of Colon Cancer trial, led to a great deal of interest for the implementation of this chemotherapeutic agent in the preoperative setting for the management of adenocarcinoma of the rectum. Despite limited in-vitro and in-vivo data with regard to the radiosensitizing properties of oxaliplatin in rectal cancer, it rapidly entered phase I-III clinical trials. This study reviews the results of these trials and the current status of oxaliplatin as a radiosensitizing agent in the neoadjuvant management of rectal cancer.

PMID:
21285866
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Icon for Lippincott Williams & Wilkins
    Loading ...
    Write to the Help Desk